Welcome to our dedicated page for Icu Medical news (Ticker: ICUI), a resource for investors and traders seeking the latest updates and insights on Icu Medical stock.
ICU Medical, Inc. (Nasdaq: ICUI) is a medical technology company that publicly reports on its performance and activities through regular news releases and investor communications. The company describes itself as a global leader in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings, and it is headquartered in San Clemente, California.
The ICUI news feed on Stock Titan aggregates company announcements that cover a range of topics important to investors and industry observers. These include quarterly earnings results, updates to fiscal year guidance, and details on product line revenues across Consumables, Infusion Systems and Vital Care. ICU Medical’s earnings releases also discuss items such as gross profit, operating expenses, non-GAAP measures like adjusted EBITDA and adjusted diluted earnings per share, and commentary from management on recent performance.
In addition to financial results, ICU Medical issues news about corporate and strategic developments. Recent disclosures include the completion of Otsuka ICU Medical LLC, a joint venture with Otsuka Pharmaceutical Factory, Inc. focused on IV solutions manufacturing and innovation in North America. The company also announces its participation in major healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference and events hosted by Piper Sandler, Wells Fargo and Morgan Stanley.
Through these updates, readers can follow how ICU Medical communicates its business progress, financial outlook and strategic initiatives. The ICUI news page on Stock Titan provides a centralized view of press releases related to earnings, guidance, joint ventures, conference appearances and other material events referenced in the company’s SEC filings. Investors and researchers can use this stream of information to monitor developments in ICU Medical’s infusion systems, consumables, vital care product lines and broader corporate activities over time.
ICU Medical, Inc. (Nasdaq:ICUI) has announced the schedule for its fourth quarter and fiscal year 2020 earnings release and conference call. The earnings report will be released on February 25, 2021, at approximately 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET. Investors can access the call at (800) 936-9761 with conference ID 8029238 or via webcast on the company's website. ICU Medical specializes in innovative medical products for infusion therapy and critical care applications, helping to achieve clinical safety and workflow efficiency.
ICU Medical announced that its Plum 360 smart infusion system received the Best in KLAS honor as the top-performing Smart Pump EMR-Integrated. This recognition, a first by KLAS Research, highlights the Plum 360's alignment with industry guidelines for interoperable infusion systems. The award reflects feedback from thousands of healthcare professionals and emphasizes ICU Medical's leadership in infusion therapy. The company aims to enhance safety through improved integration with electronic medical records (EMR) and other systems, demonstrating a commitment to innovation and customer satisfaction.
ICU Medical (Nasdaq:ICUI) announced its participation in the J.P. Morgan 39th Annual Healthcare Conference, taking place virtually from January 11-14, 2021. The company's presentation is scheduled for January 13, 2021, at 8:40 a.m. PST (11:40 a.m. EST).
The event will be webcast live, accessible via the ICU Medical website under the Investors tab. The presentation will also be available for replay.
ICU Medical, Inc. (Nasdaq:ICUI) reported Q3 2020 revenues of $318.6 million, a $11.1 million increase year-over-year. However, GAAP gross profit declined to $113.9 million with a gross margin of 36%, down from 39% in Q3 2019. Net income was $25.0 million, or $1.16 per diluted share, down from $26.6 million or $1.24 per share in the same quarter last year. Adjusted EPS rose to $1.90 from $1.65. The company narrowed its 2020 adjusted EBITDA outlook to $235-$245 million and updated EPS guidance to $6.65-$7.00.
ICU Medical, Inc. (Nasdaq:ICUI) announced its third quarter 2020 earnings release on November 5, 2020, at 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET. The call can be accessed by dialing (800) 936-9761 with conference ID 9959519 and will also be available via webcast on the company's website. ICU Medical specializes in infusion therapy and critical care products, including IV smart pumps and other innovative medical solutions aimed at enhancing clinical safety and workflow.
ICU Medical, a leader in medical products for infusion therapy and critical care, announced its participation in the Morgan Stanley 18th Annual Global Healthcare Conference scheduled for September 14-18, 2020. The company will present virtually on September 17, 2020, at 12:30 PM Eastern Time. Interested parties can access the live webcast through the company's website under the Investors tab and the Event Calendar section. The presentation will also be available for replay.
ICU Medical reported second quarter 2020 revenues of $303.4 million, a decrease from $312.3 million in Q2 2019. The GAAP gross profit rose to $106.3 million, yielding a gross margin of 35%. Net income fell to $18.9 million or $0.88 per diluted share, down from $22.8 million or $1.06 per share a year prior. Adjusted diluted EPS decreased to $1.65 from $1.99. Demand for infusion pumps remained strong amid the COVID-19 pandemic.
ICU Medical, Inc. (Nasdaq:ICUI) announced its Q1 2020 financial results, revealing a revenue of $328.6 million, down from $330.9 million in Q1 2019. The company's GAAP gross profit decreased to $121.4 million, yielding a gross margin of 37% compared to 41% last year. Net income fell to $16.8 million or $0.78 per share, down from $31.0 million or $1.44 per share in the previous year. Adjusted EBITDA also declined to $63.0 million, from $77.9 million. The company revised its full-year guidance for adjusted EBITDA and EPS downward due to external economic factors.